ArticleCancers2022
Meta-Analysis Reveals Both the Promises and the Challenges of Clinical Metabolomics.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomic data presents challenges for epidemiological meta-analysis: a case study of childhood body mass index from the ECHO consortium.Metabolomics : Official journal of the Metabolomic Society · 2024Pooled it
- A machine learning‑enhanced serum metabolomics model for non‑invasive detection of gastric cancer.Metabolomics : Official journal of the Metabolomic Society · 2026Article
- Receptor-Mitochondria Crosstalk in the Kynurenine Metabolic Pathway: Integrating Metabolomics and Clinical Mass Spectrometry.Antioxidants (Basel, Switzerland) · 2026Review
- A repository of the salivary metabolome and its key drivers in 1436 European children.EBioMedicine · 2025Article
- Securing the Future of NMR Metabolomics Reproducibility: A Call for Standardized Reporting.Analytical chemistry · 2025Review
- A Large Language Model-Powered Map of Metabolomics Research.Analytical chemistry · 2025Review
- Article
- Artificial neural network detection of pancreatic cancer from proton (1H) magnetic resonance spectroscopy patterns of plasma metabolites.Communications medicine · 2025Article
- Evaluating protocols for reproducible targeted metabolomics by NMR.The Analyst · 2024Article
- A Reproducibility Crisis for Clinical Metabolomics Studies.Trends in analytical chemistry : TRAC · 2024Article
- Metabolic Choreography of Energy Substrates During DCD Heart Perfusion.Transplantation direct · 2024Article
- Applications of chromatographic methods in metabolomics: A review.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences · 2024Review
- NMR Precision Metabolomics: Dynamic Peak Sum Thresholding and Navigators for Highly Standardized and Reproducible Metabolite Profiling of Clinical Urine Samples.Metabolites · 2024Article
- Potential Metabolite Biomarkers of Multiple Sclerosis from Multiple Biofluids.ACS chemical neuroscience · 2024Article
- Best Practices in NMR Metabolomics: Current State.Trends in analytical chemistry : TRAC · 2024Article
- Multiplatform untargeted metabolomics.Magnetic resonance in chemistry : MRC · 2023Review
- A Metabolites Merging Strategy (MMS): Harmonization to Enable Studies' Intercomparison.Metabolites · 2023Article
- Metabolome-Wide Mendelian Randomization Assessing the Causal Relationship Between Blood Metabolites and Bone Mineral Density.Calcified tissue international · 2023Article
- Circulating metabolites as potential biomarkers for the early detection and prognosis surveillance of gastrointestinal cancers.Metabolomics : Official journal of the Metabolomic Society · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Clinical metabolomics is a rapidly expanding field focused on identifying molecular biomarkers to aid in the efficient diagnosis and treatment of human diseases. Variations in study design, metabolomics methodologies, and investigator protocols raise serious concerns about the accuracy and reproducibility of these potential biomarkers. The explosive growth of the field has led to the recent availability of numerous replicate clinical studies, which permits an evaluation of the consistency of biomarkers identified across multiple metabolomics projects. Pancreatic ductal adenocarcinoma (PDAC) is the third-leading cause of cancer-related death and has the lowest five-year survival rate primarily due to the lack of an early diagnosis and the limited treatment options. Accordingly, PDAC has been a popular target of clinical metabolomics studies. We compiled 24 PDAC metabolomics studies from the scientific literature for a detailed meta-analysis. A consistent identification across these multiple studies allowed for the validation of potential clinical biomarkers of PDAC while also highlighting variations in study protocols that may explain poor reproducibility. Our meta-analysis identified 10 metabolites that may serve as PDAC biomarkers and warrant further investigation. However, 87% of the 655 metabolites identified as potential biomarkers were identified in single studies. Differences in cohort size and demographics,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.